TWI868593B - 新生黴素(novobiocin)類似物及脯胺酸之共晶型及其用途 - Google Patents

新生黴素(novobiocin)類似物及脯胺酸之共晶型及其用途 Download PDF

Info

Publication number
TWI868593B
TWI868593B TW112106332A TW112106332A TWI868593B TW I868593 B TWI868593 B TW I868593B TW 112106332 A TW112106332 A TW 112106332A TW 112106332 A TW112106332 A TW 112106332A TW I868593 B TWI868593 B TW I868593B
Authority
TW
Taiwan
Prior art keywords
proline
cocrystal
ray powder
powder diffraction
ethyl
Prior art date
Application number
TW112106332A
Other languages
English (en)
Chinese (zh)
Other versions
TW202323267A (zh
Inventor
江昕
約翰 艾倫 威林
梅蘭妮 J 畢菲
克里斯多夫 S 希迪克
傑瑞德 P 斯密特
Original Assignee
美商瑞塔醫藥有限責任公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商瑞塔醫藥有限責任公司 filed Critical 美商瑞塔醫藥有限責任公司
Publication of TW202323267A publication Critical patent/TW202323267A/zh
Application granted granted Critical
Publication of TWI868593B publication Critical patent/TWI868593B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/207—Cyclohexane rings not substituted by nitrogen atoms, e.g. kasugamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H1/00—Processes for the preparation of sugar derivatives
    • C07H1/06—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrane Compounds (AREA)
TW112106332A 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型及其用途 TWI868593B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862627570P 2018-02-07 2018-02-07
US62/627,570 2018-02-07

Publications (2)

Publication Number Publication Date
TW202323267A TW202323267A (zh) 2023-06-16
TWI868593B true TWI868593B (zh) 2025-01-01

Family

ID=65444361

Family Applications (3)

Application Number Title Priority Date Filing Date
TW112106332A TWI868593B (zh) 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型及其用途
TW108104336A TWI797249B (zh) 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型、其製造方法及用途
TW113147071A TWI915111B (zh) 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW108104336A TWI797249B (zh) 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型、其製造方法及用途
TW113147071A TWI915111B (zh) 2018-02-07 2019-02-01 新生黴素(novobiocin)類似物及脯胺酸之共晶型

Country Status (19)

Country Link
US (3) US10717755B2 (cg-RX-API-DMAC7.html)
EP (1) EP3749675B1 (cg-RX-API-DMAC7.html)
JP (3) JP2021512910A (cg-RX-API-DMAC7.html)
KR (2) KR102718111B1 (cg-RX-API-DMAC7.html)
CN (2) CN112020506B (cg-RX-API-DMAC7.html)
AR (1) AR114245A1 (cg-RX-API-DMAC7.html)
AU (3) AU2019217821B2 (cg-RX-API-DMAC7.html)
BR (1) BR112020016205A2 (cg-RX-API-DMAC7.html)
CA (2) CA3090646C (cg-RX-API-DMAC7.html)
CL (2) CL2020002051A1 (cg-RX-API-DMAC7.html)
CO (1) CO2020009761A2 (cg-RX-API-DMAC7.html)
EA (1) EA202091885A1 (cg-RX-API-DMAC7.html)
IL (2) IL315865A (cg-RX-API-DMAC7.html)
MX (2) MX2020008326A (cg-RX-API-DMAC7.html)
MY (1) MY209803A (cg-RX-API-DMAC7.html)
PE (1) PE20211446A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202007530XA (cg-RX-API-DMAC7.html)
TW (3) TWI868593B (cg-RX-API-DMAC7.html)
WO (1) WO2019156907A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
CN115181146B (zh) * 2021-04-02 2024-06-04 浙江普洛家园药业有限公司 一种新生霉素的提取工艺

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537901A (ja) * 2010-09-23 2013-10-07 ナフォーミックス リミテッド アプレピタントl−プロリン組成物および共結晶
TW201414745A (zh) * 2012-08-31 2014-04-16 Novartis Ag 用於治療病毒感染的2’-支鏈核苷
US9422320B2 (en) * 2012-02-09 2016-08-23 University Of Kansas C-terminal HSP90 inhibitors
CN106536498A (zh) * 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI542596B (zh) * 2011-05-09 2016-07-21 健生藥品公司 (2s,3r,4r,5s,6r)-2-(3-((5-(4-氟苯基)噻吩-2-基)甲基)-4-甲基苯基)-6-(羥甲基)四氫-2h-哌喃-3,4,5-三醇之l-脯胺酸及檸檬酸共晶體
CN108640910A (zh) * 2011-11-25 2018-10-12 诺弗米克斯技术有限公司 阿瑞吡坦l-脯氨酸溶剂化物-组合物和共晶体
EP2602249B1 (en) * 2011-12-06 2015-08-12 F.I.S. Fabbrica Italiana Sintetici S.p.A. Synthesis of rosuvastatin by means of co-crystals
TW201512201A (zh) * 2013-03-14 2015-04-01 Forum Pharmaceuticals Inc 化合物的多晶型及鹽類
PT3202772T (pt) * 2014-09-30 2020-11-20 Jiangsu Hengrui Medicine Co Cristal de um complexo de l-prolina/inibidor do cotransportador de sódio-glicose 2
BR112020016205A2 (pt) 2018-02-07 2020-12-15 Reata Pharmaceuticals, Inc. Formas cocristalinas de prolina e de análogo de novobiocina

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013537901A (ja) * 2010-09-23 2013-10-07 ナフォーミックス リミテッド アプレピタントl−プロリン組成物および共結晶
US9422320B2 (en) * 2012-02-09 2016-08-23 University Of Kansas C-terminal HSP90 inhibitors
TW201414745A (zh) * 2012-08-31 2014-04-16 Novartis Ag 用於治療病毒感染的2’-支鏈核苷
CN106536498A (zh) * 2014-06-24 2017-03-22 堪萨斯大学 作为hsp90抑制剂和hsp70诱导剂的具有经修饰醚基的联苯酰胺

Also Published As

Publication number Publication date
IL276583B1 (en) 2024-11-01
KR20240155354A (ko) 2024-10-28
AU2019217821B2 (en) 2022-09-08
MX2022012856A (es) 2022-11-30
SG11202007530XA (en) 2020-09-29
US11401294B2 (en) 2022-08-02
JP2024001167A (ja) 2024-01-09
AU2022283638B2 (en) 2024-07-25
WO2019156907A1 (en) 2019-08-15
AU2019217821A1 (en) 2020-09-24
US20190241599A1 (en) 2019-08-08
MX2020008326A (es) 2020-09-28
EA202091885A1 (ru) 2021-01-15
IL276583A (en) 2020-09-30
CL2020002051A1 (es) 2021-02-19
AR114245A1 (es) 2020-08-12
TW202510893A (zh) 2025-03-16
CN112020506B (zh) 2024-10-11
CN118894894A (zh) 2024-11-05
JP2021512910A (ja) 2021-05-20
US10717755B2 (en) 2020-07-21
KR102718111B1 (ko) 2024-10-17
CO2020009761A2 (es) 2020-10-30
TW201945381A (zh) 2019-12-01
EP3749675A1 (en) 2020-12-16
MY209803A (en) 2025-08-05
IL276583B2 (en) 2025-03-01
NZ767558A (en) 2024-11-29
BR112020016205A2 (pt) 2020-12-15
AU2022283638A1 (en) 2023-02-02
US20240043465A1 (en) 2024-02-08
CA3090646C (en) 2024-02-27
PE20211446A1 (es) 2021-08-05
TWI797249B (zh) 2023-04-01
US20200347088A1 (en) 2020-11-05
KR20200141985A (ko) 2020-12-21
TW202323267A (zh) 2023-06-16
CA3226385A1 (en) 2019-08-15
AU2024227646A1 (en) 2024-11-14
CL2022003784A1 (es) 2023-06-09
JP2026012851A (ja) 2026-01-27
CA3090646A1 (en) 2019-08-15
CN112020506A (zh) 2020-12-01
IL315865A (en) 2024-11-01
TWI915111B (zh) 2026-02-11
EP3749675B1 (en) 2025-12-31

Similar Documents

Publication Publication Date Title
AU2022283638B2 (en) Co-crystal forms of a novobiocin analog and proline
US20180057481A1 (en) Solid forms of cenicriviroc mesylate and processes of making solid forms of cenicriviroc mesylate
US20150183779A1 (en) Solid state form of vemurafenib choline salt
US20140050791A1 (en) Optimized Synthesis Of Pure, Non-Polymorphic, Crystalline Bile Acids With Defined Particle Size
US20260022115A1 (en) Polymorphic forms of a substituted-quinoxaline-type bridged-piperdine compound
US20240317764A1 (en) Salts and solid forms of a compound having apj receptor activity
HK40119275A (en) Co-crystal forms of a novobiocin analog and proline
US20200283381A1 (en) Solid state forms of elafibranor
EA049105B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
EA043335B1 (ru) Формы сокристаллов аналога новобиоцина и пролина
US20250059202A1 (en) Crystal form of fused ring derivative, and preparation method therefor and use thereof
RU2838992C2 (ru) Кристаллические формы ингибитора янус-киназы